Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Early evidence from the canadian experience

PLoS Currents

Volumn , Issue DEC, 2009, Pages

  Sander, Beate ^a   Bauch, Chris ^e   Fisman, David N ^a   Fowler, R ^a   Kwong, Jeffrey C ^b   McGeer, Allison ^c   Gojovic, Marija Zivkovic ^d   Krahn, Murray ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649461520     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1137     Document Type: Article

References (14)

1. Public Health Agency of Canada (2009): Guidance Document on the Use of Pandemic Influenza A (H1N1) 2009 Inactivated Monovalent Vaccine Revised November 13, 2009. Available at: http://www.phacaspc. gc.ca/alert-alerte/h1n1/vacc/pdf/monovacc-guide-eng.pdf. Accessed 2009 Nov 19.
2. Zivkovic Gojovic M, Sander B, Fisman D, Krahn MD, and Bauch CT. Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009 181: 673-680.
3. Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D, et al. Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. Emerg Infect Dis [serial on the Internet]. 2009 Dec; [Epub ahead of print]
4. OCCI (Ontario Case Costing Initiative). Costing Analysis Tool. Available from: http://www.occp.com. Last updated September 2009. Accessed October 26, 2009.
5. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, et al. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 2006; 24: 1035-1043.
6. Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. PharmacoEconomics 1999; 15: 369-376. (2008)
7. Tuite A. Estimated Rates of Hospitalization, ICU Admission, and Mortality by Age and Risk Group for 2009 H1N1 in Ontario, April to June 2009. Australian Government, Department of Health and Aging. Australian Influenza Surveillance Summary Report. No.22, 2009, Reporting Period: 3 October 2009-9 October 2009. Available from: http://www.healthemergency.gov.au. Accessed November 10, 2009.
8. Kumar A, Zarychanski R, Pinto R, et al. for the Canadian Critical Care Trials Group H1N1 Collaborative. Critically Ill Patients with 2009 Influenza A (H1N1) in Canada. JAMA 2009;302:1872-1879.
9. Statistics Canada. Mortality rate per 1,000 population. Canadian socio-economic information management system (CANSIM). 2008.
10. Waldie P, Alphonso C. Cost of vaccinating nation hits $1.5-billion and climbing. Globe and Mail. Published on Thursday, Nov. 12, 2009 12:00AM EST. Available from: http://www.theglobeandmail.com. Last updated on Friday, Nov. 13, 2009 1:57AM EST. Accessed November 18, 2009.
11. WHO. Cost-effectiveness thresholds. Available from: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 2009 Nov 19.
12. Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 2000; 17: 217-227.
13. Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62: 1013-102.
14. Kwong JC, Stukel TA, Lim J, McGeer AJ, Upshur RE, et al. The effect of universal influenza immunization on mortality and health care use. PLoS Med 2008; 5: e211.